Fatal vascular outcomes following major orthopedic surgery

Summary

Major orthopedic surgery is known to be associated with potentially serious arterial and venous vascular complications, although uncertainty exists about current event rates. Using electronic databases and investigator contact, we identified randomized and cohort studies reporting overall mortality and fatal vascular events. Where possible, studies reporting high autopsy rates (>60%) were examined. Pooled incidences were calculated from eligible studies. For Autopsy studies: Pooled overall mortality and fatal pulmonary embolism for patients undergoing elective hip and knee replacement without prophylaxis could not be calculated, while with prophylaxis they were 0.44% (95% confidence interval 0.02 to 0.87%) and 0.43% (0.01 to 0.85%). For patients undergoing hip fracture surgery, the corresponding rates without prophylaxis were 15.9% (14.5 to 17.3%) and 1.9% (1.4 to 2.4%). With prophylaxis, mortality and fatal pulmonary embolism rates were 8.5% (7.3 to 9.7%) and 1.0% (0.6 to 1.5%). Among Cohort studies: Pooled overall mortality and fatal pulmonary embolism for patients undergoing elective hip and knee replacement without prophylaxis were 0.93% (0.57 to 1.29%) and 0.36% (0.14 to 0.59%). For patients receiving prophylaxis (7 to 14 days), mortality and fatal pulmonary embolism were 0.57% (0.51 to 0.62%) and 0.18% (0.14 to 0.21%). Patients undergoing hip fracture surgery receiving prophylaxis had mortality and fatal pulmonary embolism rates of 3.2% (2.8 to 3.6%) and 0.30% (0 to 0.61%). Vascular events contributed towards approximately 50% of all deaths with similar proportions due to ischemic heart disease, cardiac failure and pulmonary embolism. In conclusion, although prophylaxis results in a reduction in overall mortality and fatal pulmonary embolism, vascular events continue to be a common cause of mortality.

Keywords

Orthopedic surgery - prophylaxis - fatal vascular outcomes

• References

• 1 Ostendorf M, Johnell O, Malchau H. et al. The epidemiology of total hip replacement in. The Netherlands and Sweden: present status and future needs. Acta Orthop Scand 2002; 73: 282-6.
• 2 Robertsson O, Dunbar MJ, Knutson K. et al. Past incidence and future demand for knee arthroplasty in Sweden: a report from the Swedish Knee Arthroplasty Register regarding the effect of past and future population changes on the number of arthroplasties performed. Acta Orthop Scand 2000; 71: 376-80.
• 3 Dahl OE, Molnar I, Vinje A. et al. Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement. Thromb Res 1988; 50: 875-84.
• 4 Dahl OE, Pedersen T, Kierulf P. et al. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993; 70: 451-8.
• 5 PEP Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
• 6 Lie SA, Engesaeter LB, Havelin LI. et al. Mortality after total hip replacement: 0–10-year follow-up of 39, 543 patients in the Norwegian Arthroplasty Register. Acta Orthop Scand 2000; 71: 19-27.
• 7 Lie SA, Engesaeter LB, Havelin I L. et al. Early postoperative mortality after 67, 548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 2002; 73: 392-9.
• 8 Seagroatt V, Tan HS, Goldacre M. et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. Br Med J 1991; 303: 1431-5.
• 9 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S.
• 10 Collins R, Scrimgeour A, Yusuf S. et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overviewof results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-73.
• 11 Prandoni P, Bilora F, Marchiori A. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
• 12 Armitage P, Berry G.. Statistical Methods in Epidemiology. Blackwell Scientific Publications LTP 1987; 455-83.
• 13 Sheppeard H, Henson J, Ward DJ. et al. A clinicopathological study of fatal pulmonary embolism in a specialist orthopaedic hospital. Arch Orthop Trauma Surg 1981; 99: 65-71.
• 14 Perez JV, Warwick DJ, Case CP. et al. Death after proximal femoral fracture--an autopsy study. Injury 1995; 26: 237-40.
• 15 Eriksson I B, Bauer KA, Lassen MR. et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolismafter hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
• 16 Frostick SP, Fowler S.. British Orthopaedic Association Congress, September. 1995
• 17 Frostick SP. Death after joint replacement. Haemostasis 2000; 30 (Suppl. 02) Suppl 84-7.
• 18 Grion AM, Gallo U, Bano F. et al. Difference in mortality after hip fracture is associated with postdischarge prescription of antithrombotic prophylaxis: a case-control study. Clin Appl Thromb Hemost 2002; 8: 143-6.
• 19 Barrett JA, Baron JA, Beach ML. Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int 2003; 14: 889-94.
• 20 van Balen R, Steyerberg EW, Polder JJ. et al. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop 2001; 390: 232-43.
• 21 Zuckerman JD. Hip fracture. N Engl J Med 1996; 334: 1519-25.
• 22 Aharonoff GB, Koval KJ, Skovron ML. et al. Hip fractures in the elderly: predictors of one year mortality. J Orthop Trauma 1997; 11: 162-5.
• 23 Schurch MA, Rizzoli R, Mermillod B. et al. Aprospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996; 11: 1935-42.
• 24 Todd CJ, Freeman CJ, Camilleri-Ferrante C. et al. Differences in mortality after fracture of hip: the East Anglian Audit. Br Med J 1995; 310: 904-8.
• 25 Lawrence VA, Hilsenbeck SG, Noveck H. et al. Medical complications and outcomes after hip fracture repair. Arch Intern Med 2002; 162: 2053-7.
• 26 National Hospital Discharge Survey. 1979–1999 Multi-year Public-use data file documentation. US Department of Health and Human Services, Public Health Service, National Center for Health Statistics. 2004.
• 27 National Center for Health Statistics. Mortality for 1979–1999 with ICD 9 codes, CDC Wonder on the web. 2004.
• 28 Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979–1998: an analysis usingmultiple-causemortality data. Arch Intern Med 2003; 163: 1711-7.
• 29 Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis. Clin Orthop 1989; 242: 212-31.
• 30 Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000; 71: 47-50.
• 31 Dahl OE, Gudmundsen TE, Bjornara BT. et al. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3, 954 patients. Acta Orthop Scand 2003; 74: 299-304.
• 32 Havig O.. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand 1977; (Suppl. 04) Suppl 78: 1.
• 33 Karwinski B. The significance of autopsy in modern medicine. A study from western Norway. PhD Thesis. 1995. Norway: University of Bergen;
• 34 Hunter JB, Frostick SP. Dalteparin (Fragmin) for the prevention of early mortality after orthopedic surgery. Thromb Haemost 1995; 73 [Abstract 977].
• 35 Haas S, Wolf H, Kakkar AK. et al. Prevention of fatal pulmonary embolismand mortality in surgical patients – a double blind comparison of low-molecular weight heparin with unfractionated heparin. Thromb Haemost In press.
• 36 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351-75.
• 37 Bergqvist D, Fredin H. Pulmonary embolism and mortality in patients with fractured hips--a prospective consecutive series. Eur J Surg 1991; 157: 571-4.
• 38 Schroder HM, Andreassen M. Autopsy-verified major pulmonary embolismafter hip fracture. Clin Orthop 1993; 293: 196-203.
• 39 Gruber UF. Prevention of fatal pulmonary embolismin patients with fractures of the neck of the femur. Surg Gynecol Obstet 1985; 161: 37-42.
• 40 Coventry MB, Nolan DR, Beckenbaugh RD. “Delayed” prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg Am 1973; 55: 1487-92.
• 41 Warwick D, Williams MH, Bannister GC. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br 1995; 77: 6-10.
• 42 Ansari S, Warwick D, Ackroyd CE. et al. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. J Arthroplasty 1997; 12: 599-6.
• 43 Fender D, Harper WM, Thompson JR. et al. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 1997; 79: 896-9.
• 44 Royal College of Surgeons of England. National Total Hip Replacement Outcome Study. 2000. London: RCS;
• 45 Lubinus P, Klauser W.. Mortality after total hip replacement due to fatal pulmonary embolism. Presented at the 1^st SICOT/SIROT Annual International Conference, August 31-September 1, 2001, Paris, France Abstract #114.
• 46 Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg Am 2002; 84: 562-72.
• 47 Bannister GC, Gibson AG, Ackroyd CE. et al. The fixation and prognosis of trochanteric fractures. Arandomized prospective controlled trial. Clin Orthop 1990; 254: 242-6.